JP7623497B2 - ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ - Google Patents

ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ Download PDF

Info

Publication number
JP7623497B2
JP7623497B2 JP2023539973A JP2023539973A JP7623497B2 JP 7623497 B2 JP7623497 B2 JP 7623497B2 JP 2023539973 A JP2023539973 A JP 2023539973A JP 2023539973 A JP2023539973 A JP 2023539973A JP 7623497 B2 JP7623497 B2 JP 7623497B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023539973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501539A (ja
JP2024501539A5 (https=
Inventor
ローラン・ゴーチエ
アリアーヌ・シーレン
ベンヤミン・ロッシ
セリーヌ・アマラ
セリーヌ・ニコラッツィ
マリエル・シロン
フランシス・ドゥフィユー
アンジェラ・ヴィロン－オッドス
ヨッヘン・ベニンガ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2024501539A publication Critical patent/JP2024501539A/ja
Publication of JP2024501539A5 publication Critical patent/JP2024501539A5/ja
Priority to JP2025005123A priority Critical patent/JP2025063183A/ja
Application granted granted Critical
Publication of JP7623497B2 publication Critical patent/JP7623497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023539973A 2020-12-31 2021-12-30 ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ Active JP7623497B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025005123A JP2025063183A (ja) 2020-12-31 2025-01-15 ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20306717 2020-12-31
EP20306717.8 2020-12-31
US202163256950P 2021-10-18 2021-10-18
US63/256,950 2021-10-18
PCT/IB2021/062494 WO2022144836A1 (en) 2020-12-31 2021-12-30 Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025005123A Division JP2025063183A (ja) 2020-12-31 2025-01-15 ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ

Publications (3)

Publication Number Publication Date
JP2024501539A JP2024501539A (ja) 2024-01-12
JP2024501539A5 JP2024501539A5 (https=) 2024-11-07
JP7623497B2 true JP7623497B2 (ja) 2025-01-28

Family

ID=79316794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023539973A Active JP7623497B2 (ja) 2020-12-31 2021-12-30 ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
JP2025005123A Pending JP2025063183A (ja) 2020-12-31 2025-01-15 ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025005123A Pending JP2025063183A (ja) 2020-12-31 2025-01-15 ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ

Country Status (11)

Country Link
US (2) US11692039B2 (https=)
EP (1) EP4271709A1 (https=)
JP (2) JP7623497B2 (https=)
KR (2) KR20250152662A (https=)
AU (1) AU2021414400A1 (https=)
CA (1) CA3206883A1 (https=)
CO (1) CO2023008958A2 (https=)
IL (1) IL304124A (https=)
MX (1) MX2023007901A (https=)
TW (1) TWI905354B (https=)
WO (1) WO2022144836A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025063183A (ja) * 2020-12-31 2025-04-15 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3313876T3 (da) * 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner
KR20250017240A (ko) 2022-05-27 2025-02-04 사노피 FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자
KR20240114678A (ko) * 2023-01-16 2024-07-24 주식회사 드노보 바이오테라퓨틱스 신규한 항-NKp46 항체 및 이의 용도
EP4438614A1 (en) * 2023-03-31 2024-10-02 Sanofi Methods for purifying heteromultimeric antibodies
WO2024224313A1 (en) * 2023-04-24 2024-10-31 Sanofi Use of cd123 nk cell engager for treating aml and related disorders
US20250064935A1 (en) * 2023-07-13 2025-02-27 Sanofi Natural killer cells and cd123 nk cell engager combination therapy
US20250195653A1 (en) * 2023-11-28 2025-06-19 Sanofi Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
WO2026055280A1 (en) * 2024-09-04 2026-03-12 Sanofi Interleukin 2 (il-2) and cd123 nk cell engager combination therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521400A (ja) 2014-06-27 2017-08-03 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
JP2018513831A (ja) 2015-01-23 2018-05-31 サノフイ 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体
JP2018524326A (ja) 2015-06-23 2018-08-30 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ｎｋエンゲイジャータンパク質
JP2019503713A (ja) 2015-12-28 2019-02-14 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ＮＫｐ４６結合タンパク質の可変領域
JP2019531701A (ja) 2016-07-18 2019-11-07 サノフイＳａｎｏｆｉ Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
JP4327350B2 (ja) 1997-11-17 2009-09-09 マイクロメット アーゲー エピトープへの結合能力を保持する結合部位ドメインの同定のための新規方法
AU773029B2 (en) 1999-02-08 2004-05-13 Medvet Science Pty. Ltd. Cytokine-binding domain
EP1161453A4 (en) 1999-02-08 2005-01-05 Medvet Science Pty Ltd CYTOKIN-BINDING DOMAIN
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
NZ521255A (en) 2000-03-06 2007-01-26 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
RU2005137325A (ru) 2003-05-31 2006-09-10 Микромет Аг (De) Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
WO2009070844A1 (en) 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
AU2011217728B2 (en) 2010-02-17 2013-03-14 Csl Limited Compositions and methods for targeting type 1 interferon producing cells
CA2802046C (en) 2010-06-07 2018-12-11 Stepan Company Dilutable biocidal compositions and methods of use
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
EP2626069A4 (en) 2010-10-06 2014-03-19 Univ Tokyo Prophylactic and/or therapeutic agent against lymphedema
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
EP2658869B1 (en) 2010-12-30 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US20160046718A1 (en) 2013-03-14 2016-02-18 Csl Limited Agents that neutralize il-3 signalling and uses thereof
WO2014138805A1 (en) 2013-03-14 2014-09-18 Csl Limited Anti il-3r alpha agents and uses thereof
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
PL3119807T3 (pl) 2014-03-19 2019-09-30 Cellectis Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
US20180134795A1 (en) 2014-06-17 2018-05-17 Cellectis Cd123 specific multi-chain chimeric antigen receptor
WO2015197598A2 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
CN105367657B (zh) 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
MA40609B1 (fr) 2014-09-05 2020-05-29 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
DK3313876T3 (da) 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner
JP6768011B2 (ja) 2015-06-23 2020-10-14 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｃｄ１２３抗体との抗体薬物複合体
WO2017025323A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
EP3383431A4 (en) 2015-12-02 2019-08-28 Agenus Inc. ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
EP3713959A1 (en) * 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
KR20210133261A (ko) 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질
TWI905354B (zh) * 2020-12-31 2025-11-21 法商英耐特醫藥公司 結合至NKp46及CD123之多功能自然殺手 (NK) 細胞接合體
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521400A (ja) 2014-06-27 2017-08-03 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
JP2018513831A (ja) 2015-01-23 2018-05-31 サノフイ 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体
JP2018524326A (ja) 2015-06-23 2018-08-30 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ｎｋエンゲイジャータンパク質
JP2019503713A (ja) 2015-12-28 2019-02-14 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ＮＫｐ４６結合タンパク質の可変領域
JP2019531701A (ja) 2016-07-18 2019-11-07 サノフイＳａｎｏｆｉ Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025063183A (ja) * 2020-12-31 2025-04-15 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ

Also Published As

Publication number Publication date
AU2021414400A1 (en) 2023-08-17
US11692039B2 (en) 2023-07-04
IL304124A (en) 2023-09-01
EP4271709A1 (en) 2023-11-08
KR20230127306A (ko) 2023-08-31
MX2023007901A (es) 2023-07-11
US20220213202A1 (en) 2022-07-07
US20230416383A1 (en) 2023-12-28
KR102868401B1 (ko) 2025-10-14
CO2023008958A2 (es) 2023-08-18
JP2025063183A (ja) 2025-04-15
AU2021414400A9 (en) 2024-10-17
WO2022144836A1 (en) 2022-07-07
TW202241952A (zh) 2022-11-01
JP2024501539A (ja) 2024-01-12
KR20250152662A (ko) 2025-10-23
TWI905354B (zh) 2025-11-21
CA3206883A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
JP7623497B2 (ja) ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
JP6496349B2 (ja) ヒト及び非ヒトｃｄ３に結合可能なｃｄ３結合分子
JP2022507295A (ja) 治療用ＳＩＲＰα抗体
JP2020514363A (ja) 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５
AU2022244114A1 (en) TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3
US12030951B2 (en) Anti-OX40 antibody and uses thereof
US20240294634A1 (en) Treatment of cancer with ilt-2 inhibitors
CN117255807A (zh) 与NKp46和CD123结合的多功能自然杀伤（NK）细胞接合器
WO2021207681A1 (en) Targeted reduction of activated immune cells
JP2025541340A (ja) Ｃｕｂ ｄｏｍａｉｎ－ｃｏｎｔａｉｎｉｎｇ ｐｒｏｔｅｉｎ １（ｃｄｃｐ１）に対する抗体およびその使用
US20250064935A1 (en) Natural killer cells and cd123 nk cell engager combination therapy
US20250230234A1 (en) Anti-gprc5d antibodies and compositions
WO2024251884A1 (en) Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
WO2025083273A1 (en) Binding molecules
CN121511253A (zh) Cd123 nk细胞接合器用于治疗aml和相关障碍的用途
EP4229094A1 (en) Multispecific binding compounds that bind to pd-l1
HK40107037A (zh) 抗cd161抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241029

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250116

R150 Certificate of patent or registration of utility model

Ref document number: 7623497

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150